Skip to Main Content
Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our signal to daydream about weekend plans. Once again, our agenda is exceedingly modest. We hope to catch up on our reading and napping, and hang with one or two short people. And how about you? Anything interesting planned? Midsummer is already here, so enjoy the great outdoors while you can. You could make time for someone special or take up a new hobby. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon …

President Trump will sign legislation to reauthorize the Prescription Drug User Fee Act, Regulatory Focus says. The U.S. Senate on Thursday followed the U.S. House and passed a measure to ensure industry fees are paid to the Food and Drug Administration user fee programs for prescription drugs, generic drugs, and medical devices for the next five years, STAT notes. Trump wanted to double industry fees.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Memo to John Jenkins. Janet Woodcock is YOUR BOSS. She can overrule everybody except God, and I’m not entirely sure of that one either.

  • As your STAT colleague observed this ‘Right To Try’ bill “… wouldn’t require drug makers to provide the drugs or ask insurance companies to cover the treatments.” So patients will have the right to try to get a drug companies may not want to supply and no one will pay for. A wonderful campaign promise that is essntially ________ . [Choose your own adjective]

Comments are closed.